An Investigation of Popping During Radiofrequency Ablation After Lenvatinib Administration for Hepatocellular Carcinoma.

Autor:	Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan; toruishi@ngt.saiseikai.or.jp., Hasegawa I; Department of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan., Hirosawa H; Department of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan., Honmou T; Department of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan., Sakai N; Department of Clinical Engineering, Saiseikai Niigata Hospital, Niigata, Japan., Igarashi T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Yamazaki S; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Kobayashi T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Sato T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Iwanaga A; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Sano T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Yokoyama J; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Honma T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2023 Mar-Apr; Vol. 37 (2), pp. 836-840.
DOI:	10.21873/invivo.13150
Abstrakt:	Background/aim: Lenvatinib is available as a molecular target agent for hepatocellular carcinoma (HCC). In this study, we investigated the popping phenomena in patients with HCC who underwent radiofrequency ablation (RFA) after taking lenvatinib. Patients and Methods: Fifty-nine patients with HCC between 21-30 mm in diameter and no history of systemic treatment were enrolled in the study. The patients underwent RFA using a VIVA RFA SYSTEM with an ablation tip of 30 mm in length. For the initial lenvatinib administration, 16 patients had an adequate course of treatment and were treated with RFA as add-on therapy (combination group). The other 43 patients were treated by RFA monotherapy (monotherapy group). The popping frequency during RFA was recorded and compared. Results: Popping frequency in the combination group (RFA combined with lenvatinib) was significantly higher than that in the monotherapy group. There was no significant difference between the combination group and the monotherapy group in ablation time, maximum output level, tumour temperature after ablation, or initial resistance value. Conclusion: Popping frequency was significantly higher in the combination group. It is possible that the intra-tumour temperature increased rapidly during RFA in the combination group due to the inhibitory effect of lenvatinib on tumour angiogenesis, leading to the occurrence of popping. Further studies are needed to investigate popping after RFA, and precise protocols need to be developed. (Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu